Vertex announces 12-week on-treatment data and svr4 from phase 2 study of interferon-free (all-oral) treatment regimen of incivek®, vx-222 and ribavirin in people with genotype 1 hepatitis c

Cambridge, mass.--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced interim data from two treatment arms of the phase 2 zenith study evaluating an interferon-free (all-oral) treatment regimen of the non-nucleoside polymerase inhibitor vx-222 in combination with incivek ® (telaprevir) tablets and ribavirin in people with genotype 1a or 1b hepatitis c who were new to treatment. interim data showed that viral loads were below the lower limit of quantification (<25 iu/ml:
VRTX Ratings Summary
VRTX Quant Ranking